How AbbVie Could Make an Entry Into This Rapidly Growing Drug Market

Submitted by admin on July 29, 2021 - 11:12am

Source:

Motley Fool

News Tags:

Headline:

snippet:

The FDA breakthrough therapy designation for AbbVie and Roche's Venclexta and azacitidine comes following impressive results in the phase 1b study.
The drug combo helped nearly two-thirds of patients get off of red blood cell or platelet transfusions.
AbbVie also expects Venclexta to be approved for two other indications by next year.

Search form